The programme will continue a long-running area of research to produce uniquely reliable answer to important clinical questions concerned with the benefits and the main risks of treatments for various cancers, which includes breast cancer, lymphomas and all cancers diagnosed in children, teenagers and young adults. All currently available treatments have both short term side-effects, which are generally well documented, as well as less well studied long-term hazards. For example, our previous research has developed a dose-response relationship for use by clinicians to predict the radiation-related ischaemic heart disease risk for individual women irradiated for breast cancer, based on their cardiac radiation dose and their pre-existing risk factors. Our future work will further develop these risk/benefit prediction models to include valvular heart disease and pericarditis in breast cancer radiotherapy and for ischaemic heart disease, valvular heart disease, and heart failure in Hodgkin lymphoma radiotherapy. In addition, we will bring together the results from a number of treatment trials of anthracyclines for various cancers to reliably determine the risks of cardiovascular disease from these therapies. We will also analyse several large cohorts to more precisely determine the risk of cardiovascular disease from various cancer treatments using data from cancer registries that include around 2 million women with breast cancer and also determine these risks in children, teenagers and young adults using UK data on around 250,000 cancer survivors.